

# Together against Covid-19 Pandemic

## Company interested in cooperation:

### UNIVERCELLS

**Member Profile:** Univercells delivers novel technologies and solutions breaking the barriers to bioproduction.

## Contact Person (Name and Position):

### Julien Declerck – Business Development

**What can we offer:** [KEYWORDS: research infrastructure, specialized personnel, technologies, BSL-2 laboratory, BSL-3 laboratory, vaccine technology, bioreactors, single-use technology, process development, manufacturing facilities, CDMO services for viral vectors]

Univercells is an innovative bioprocessing provider focused on increasing the availability of affordable biologics. Capitalizing on unmatched bioprocessing and engineering expertise, the company is offering leading-edge manufacturing solutions to alleviate the industry's current shortfall in supply of cell and gene therapies, vaccines and biotherapeutics. Univercells is dedicated to deliver technologies, services and turnkey solutions to accompany industry experts unlock and expedite critically needed therapies. Univercells technologies include a novel high-density fixed-bed bioreactor system and a fully automated vaccine manufacturing line. A global company headquartered in Gosselies, Belgium, Univercells benefits from the support regional and national players as well as from the Bill & Melinda Gates Foundation (BMGF), Global Health Investment Fund (GHIF), European Investment Bank (EIB) and other international players in the health industry.

## What are we looking for:

### Partnership - Biomanufacturing technology and services for scaling up COVID-19 vaccine candidate production

Univercells develops high-performance manufacturing technology to rapidly and cost-effectively scale-up production of COVID-19 viral vaccines. Our subsidiary Exothera, has the capabilities to do contract manufacture and development of these vaccines. We would therefore invite all developers of COVID-19 vaccine candidates to reach out to us. By combining expertise, we could bring a very interesting value proposition to the multiple funding initiatives being launched at present. In short,

- Vaccine co-development projects
- Co-applicants for non-dilutive funding
- Technology collaborations



**Useful links:**

**Univercells:** <https://www.univercells.com/>

**Please contact us here:**

**Julien Declerck – Business Development** ([j.declerck@univercells.com](mailto:j.declerck@univercells.com), +32473190946)